Limits...
Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study.

Aberer W - Arch Drug Inf (2009)

Bottom Line: Second-generation antihistamines have been shown to be safe and effective for the treatment of symptoms of allergic disease.A significant reduction in severity scores was observed in all symptom subgroups (P < 0.001).Thirty-one subjects (3.2%) experienced adverse events.

View Article: PubMed Central - PubMed

Affiliation: Department of Environmental Dermatology, Medical University of Graz Graz, Austria.

ABSTRACT
INTRODUCTION: The rates of allergic rhinitis, allergic asthma, and atopic eczema range from 6% to 16% globally. Second-generation antihistamines have been shown to be safe and effective for the treatment of symptoms of allergic disease. This study investigated the efficacy and safety of desloratadine, a nonsedating second-generation antihistamine, in the treatment of common allergy symptoms. METHODS: In this open-label, uncontrolled, non-randomized, observational study, subjects (N = 973) with allergy symptoms were given desloratadine 5 mg daily for 3 weeks. Nasal, ocular, and dermal symptom severity was rated as asymptomatic, mild, moderate, or severe; changes in the percentage of subjects in each severity category were assessed. Overall efficacy and tolerability of desloratadine treatment were evaluated separately by physicians and subjects. RESULTS: Allergic rhinitis was the most frequent diagnosis, occurring in 59.0% of subjects. Approximately 40% of subjects had received previous treatment with other antihistamines, systemic/topical glucocorticosteroids, or beta-sympathicomimetics. Slightly more than half of subjects received concomitant medication during the study; 263 (53.0%) of those used intranasal steroids. A significant reduction in severity scores was observed in all symptom subgroups (P < 0.001). Desloratadine efficacy was judged to be excellent or good by 90.2% of physicians and 88.6% of subjects; 82.5% of investigators and 80.9% of subjects considered it more effective than previous therapy. The tolerability of desloratadine was rated excellent or good by 97.0% of both groups. Thirty-one subjects (3.2%) experienced adverse events. CONCLUSIONS: In an open-label, uncontrolled, non-randomized, observational study allergy symptoms improved significantly in subjects treated with desloratadine.

No MeSH data available.


Related in: MedlinePlus

Desloratadine efficacy (A) and tolerability (B) as rated by physicians and subjects at endpoint. Efficacy and tolerability were rated as excellent, good, moderate, or inadequate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2721966&req=5

fig04: Desloratadine efficacy (A) and tolerability (B) as rated by physicians and subjects at endpoint. Efficacy and tolerability were rated as excellent, good, moderate, or inadequate.

Mentions: Desloratadine efficacy was determined to be excellent or good by 90.2% of physicians and 88.5% of subjects at the end of therapy (Figure 4). Moreover, approximately 97% of participants in both groups rated the tolerability of desloratadine with these top 2 descriptors. Investigators (82.5%) and subjects (80.9%) described treatment with desloratadine as being better than previous allergy therapy. Of all subjects remaining on any medication at endpoint, 88.0% elected to continue treatment with desloratadine.


Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study.

Aberer W - Arch Drug Inf (2009)

Desloratadine efficacy (A) and tolerability (B) as rated by physicians and subjects at endpoint. Efficacy and tolerability were rated as excellent, good, moderate, or inadequate.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2721966&req=5

fig04: Desloratadine efficacy (A) and tolerability (B) as rated by physicians and subjects at endpoint. Efficacy and tolerability were rated as excellent, good, moderate, or inadequate.
Mentions: Desloratadine efficacy was determined to be excellent or good by 90.2% of physicians and 88.5% of subjects at the end of therapy (Figure 4). Moreover, approximately 97% of participants in both groups rated the tolerability of desloratadine with these top 2 descriptors. Investigators (82.5%) and subjects (80.9%) described treatment with desloratadine as being better than previous allergy therapy. Of all subjects remaining on any medication at endpoint, 88.0% elected to continue treatment with desloratadine.

Bottom Line: Second-generation antihistamines have been shown to be safe and effective for the treatment of symptoms of allergic disease.A significant reduction in severity scores was observed in all symptom subgroups (P < 0.001).Thirty-one subjects (3.2%) experienced adverse events.

View Article: PubMed Central - PubMed

Affiliation: Department of Environmental Dermatology, Medical University of Graz Graz, Austria.

ABSTRACT
INTRODUCTION: The rates of allergic rhinitis, allergic asthma, and atopic eczema range from 6% to 16% globally. Second-generation antihistamines have been shown to be safe and effective for the treatment of symptoms of allergic disease. This study investigated the efficacy and safety of desloratadine, a nonsedating second-generation antihistamine, in the treatment of common allergy symptoms. METHODS: In this open-label, uncontrolled, non-randomized, observational study, subjects (N = 973) with allergy symptoms were given desloratadine 5 mg daily for 3 weeks. Nasal, ocular, and dermal symptom severity was rated as asymptomatic, mild, moderate, or severe; changes in the percentage of subjects in each severity category were assessed. Overall efficacy and tolerability of desloratadine treatment were evaluated separately by physicians and subjects. RESULTS: Allergic rhinitis was the most frequent diagnosis, occurring in 59.0% of subjects. Approximately 40% of subjects had received previous treatment with other antihistamines, systemic/topical glucocorticosteroids, or beta-sympathicomimetics. Slightly more than half of subjects received concomitant medication during the study; 263 (53.0%) of those used intranasal steroids. A significant reduction in severity scores was observed in all symptom subgroups (P < 0.001). Desloratadine efficacy was judged to be excellent or good by 90.2% of physicians and 88.6% of subjects; 82.5% of investigators and 80.9% of subjects considered it more effective than previous therapy. The tolerability of desloratadine was rated excellent or good by 97.0% of both groups. Thirty-one subjects (3.2%) experienced adverse events. CONCLUSIONS: In an open-label, uncontrolled, non-randomized, observational study allergy symptoms improved significantly in subjects treated with desloratadine.

No MeSH data available.


Related in: MedlinePlus